Question Everything. See who's reporting it.

Alembic Pharmaceuticals receives USFDA approval for Binimetinib Tablets, 45 mg

Source: Business Standard

The story in brief

Alembic Pharmaceuticals received USFDA approval for Binimetinib Tablets, 45 mg, following tentative approval for the 15 mg formulation. The approved ANDA is therapeutically equivalent to Mektovi Tablets, 15 mg of Array. Binimetinib, a kinase inhibitor, is indicated for unresectable or metastatic melanoma with BRAF V600E/V600K mutations, in combination with encorafenib, and for metastatic NSCLC with BRAF V600E mutations.

NEWXFree on Android and iPhone. Open in NEWX